Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma

To determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of dasatinib, an inhibitor of the Src family kinase proteins, with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, among recurrent malignant glioma patients. Once daily dasatinib was escalated in...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Reardon, David A., Vredenburgh, James J., Desjardins, Annick, Peters, Katherine B., Sathornsumetee, Sith, Threatt, Stevie, Sampson, John H., Herndon, James E., Coan, April, McSherry, Frances, Rich, Jeremy N., McLendon, Roger E., Zhang, Steven, Friedman, Henry S.
Format: Artigo
Sprog:Inglês
Udgivet: 2012
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3690584/
https://ncbi.nlm.nih.gov/pubmed/22407177
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-012-0848-x
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker